DOCK1 and neoplasm: Collectively, these results indicated that DOCK1 levels regulate the strength of metformin’s anti-tumor effects on liver cancer, while suppression of DOCK1 sensitizes liver cancer to metformin in both patient-derived HCC organoids in vitro and mouse models in vivo.